1-[(2-hydroxyethyl)thio]propan-2-ol

Endpoint summary

Description of key information

An assessment was performed based on the outcome of a short-term repeated-dose toxicity study performed on the substance via the oral route to determine the acute oral toxicity of the registered substance. As a conclusion 1-[(2-hydroxyethyl)thio]propan-2-ol is expected to have a low acute oral toxicity with an LD50 > 2000 mg/kg.

In accordance with Annex VIII of REACH, Column 2, testing by the inhalation and dermal routes is only appropriate if exposure of humans via these routes is likely. 1-[(2-hydroxyethyl)thio]propan-2-ol is not made available on the EU market as a monomer and is imported already polymerised. Therefore no exposure of humans via the dermal and inhalation routes is expected.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

other: Expert assessment

Adequacy of study:

key study

Study period:

August 11, 2017

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Assessment based on the outcome of a short-term repeated-dose toxicity study performed on the substance via the oral route.

Qualifier:

no guideline followed

Principles of method if other than guideline:

Assessment based on the outcome of a short-term repeated-dose toxicity study performed on the substance via the oral route.

GLP compliance:

no

Test type:

other: Assessment based on the outcome of a short-term repeated-dose toxicity study performed on the substance via the oral route.

Limit test:

no

Sex:

male/female

Key result

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

other: weight of evidence

see attached report.

Interpretation of results:

GHS criteria not met

Conclusions:

1-[(2-hydroxyethyl)thio]propan-2-ol is expected to have a low acute oral toxicity with an LD50 > 2000 mg/kg.

Executive summary:

An assessment was performed based on the outcome of a short-term repeated-dose toxicity study performed on the substance via the oral route to determine the acute oral toxicity of the registered substance. As a conclusion 1-[(2-hydroxyethyl)thio]propan-2-ol is expected to have a low acute oral toxicity with an LD50 > 2000 mg/kg. The substance did not meet the criteria for classification according to Regulation (EC) No.1272/2008.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

Assessment based on the outcome of a short-term repeated-dose toxicity study performed on the substance via the oral route.

Acute toxicity: via inhalation route

Link to relevant study records

Reference

Endpoint:

acute toxicity: inhalation

Data waiving:

study scientifically not necessary / other information available

Justification for data waiving:

the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size

Justification for type of information:

JUSTIFICATION FOR DATA WAIVING
In accordance with Annex VIII of REACH, Column 2, testing via inhalation is appropriate if exposure of humans is likely. 1-[(2-hydroxyethyl)thio]propan-2-ol is not made available on the EU market as a monomer and is imported already polymerised. Therefore no exposure of humans via inhalation is expected.

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Data waiving:

study scientifically not necessary / other information available

Justification for data waiving:

the study does not need to be conducted because skin contact in production and/or use is not likely

Justification for type of information:

JUSTIFICATION FOR DATA WAIVING
In accordance with Annex VIII of REACH, Column 2, testing by the dermal route is appropriate if exposure of humans is likely via this route. 1-[(2-hydroxyethyl)thio]propan-2-ol is not made available on the EU market as a monomer and is imported already polymerised. Therefore no exposure of humans by the dermal route is expected in production and/or use.

Endpoint conclusion

Endpoint conclusion:

no study available

Justification for classification or non-classification

An assessment was performed based on the outcome of a short-term repeated-dose toxicity study performed on the substance via the oral route to determine the acute oral toxicity of the registered substance. As a conclusion 1-[(2-hydroxyethyl)thio]propan-2-ol is expected to have a low acute oral toxicity with an LD50 > 2000 mg/kg. The substance did not meet the criteria for classification according to Regulation (EC) No.1272/2008.

In accordance with Annex VIII of REACH, Column 2, no acute testing of 1-[(2-hydroxyethyl)thio]propan-2-ol via the inhalation and dermal routes was performed as exposure to humans by these routes is unlikely.